Xenetic Bioscience

Xenetic Biosciences, Inc. is a biopharmaceutical company based in Framingham, Massachusetts, specializing in the development of innovative oncology therapeutics and personalized cancer treatments. The company is advancing its XCART platform, a personalized chimeric antigen receptor T cell (CAR T) technology designed to target specific tumor neoantigens in individual patients, particularly those with B-cell lymphomas. Additionally, Xenetic is enhancing treatment outcomes through its DNase platform, which targets neutrophil extracellular traps implicated in cancer progression and resistance to therapies. The company is also engaged in the collaboration and partnership with major pharmaceutical firms, leveraging its proprietary PolyXen drug delivery platform to improve the efficacy of drugs and vaccines across various medical areas. Xenetic's investigational drug candidate, XBIO-101, is being developed for the treatment of progestin-resistant endometrial cancer.